Previous 10 | Next 10 |
FNCB Bancorp Inc. (FNCB) is expected to report for Q1 2024 Civista Bancshares Inc. (CIVB) is expected to report $0.6 for Q3 2023 ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023 Grupo Televisa S.A. (TV) is expected to report $0.02 for Q3 2023 Red River...
Dr. Reddy's Laboratories Ltd (RDY) is expected to report $0.88 for Q2 2024
2023-08-23 17:02:58 ET Summary Dr. Reddy's Laboratories stock remains an attractive long-term investment. The company's Q1 FY'24 earnings showed strong growth in total revenues and gross margins, driven by sales expansion in its generic business. RDY's growth is supported by m...
2023-08-18 13:09:45 ET Summary On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous qu...
2023-08-10 16:04:28 ET Indian drugmaker Dr. Reddy's Laboratories ( NYSE: RDY ) said it has launched a generic equivalent of AstraZeneca's ( AZN ) diabetes medication Kombiglyze XR for the US market. The product, which is an extended release formulation of saxagliptin and met...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent ge...
2023-08-03 14:13:02 ET Summary Today, we are circling back on Eagle Pharmaceuticals for the first time in a while as the shares are down big since the start of 2022. The company is managing to stay profitable as it manages through a period of sales declines. Management did jus...
2023-07-26 17:00:22 ET Dr Reddy's Laboratories Ltd (RDY) Q1 2024 Earnings Conference Call July 26, 2023, 10:00 AM ET Company Participants Richa Periwal - IR Erez Israeli - CEO Parag Agarwal - CFO Conference Call Participants Kunal Dhamesha - Macquarie...
2023-07-26 16:46:16 ET Dr. Reddy's press release ( NYSE: RDY ): Q1 GAAP EPS of ₹84.22. Revenue of ₹6.7B. For further details see: Dr. Reddy's GAAP EPS of ₹84.22, revenue of ₹6.7B
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Fina...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of...